Myriam Drysdale, Thor Hautekiet, Moushmi Singh, Joris Hautekiet, Linda Ludikhuyze, Vishal Patel, Daniel C Gibbons, Dorothée De Roeck, Kirsten Colpaert, Emily J Lloyd, Eva Van Braeckel
OBJECTIVE: Sotrovimab, a dual-action, engineered human monoclonal antibody, has been demonstrated to significantly reduce the risk of hospitalisation and death in high-risk patients with COVID-19. Here, we describe the real-world use of, and outcomes from, sotrovimab treatment in Belgium during the Delta and Omicron waves among patients with COVID-19 at high risk of developing severe disease. METHODS: This was a multicentric, single-arm observational cohort study of non-hospitalised patients receiving outpatient sotrovimab treatment between 1 November 2021 and 2 August 2022 at nine hospitals in Belgium...
July 31, 2024: Acta Clinica Belgica